Author Archives: Isaura Santos

DiscoveryBioMed Developing A New Small Molecule Monotherapy For Cystic Fibrosis Patients

DiscoveryBioMed, Inc. (DMB) has discovered and is currently developing a new class of small molecule monotherapy that utilizes the pathophysiological features of cystic fibrosis and works on two drug targets. In Cystic Fibrosis, patients’ production of the CFTR protein and ENaC ion channel is abnormal, leading to a dysfunctional CFTR activity and over-activity of ENaC.

AbbVie Scholarship For Students With CF Now Accepting Applications

AbbVie recently announced that the 2015 AbbVie CF Scholarship is now open and accepting applications from both graduate and undergraduate students. This scholarship supports and honors young adults suffering with cystic fibrosis (CF) in their pursuit of higher education. Students can apply for the scholarship until May 27, 2015, 10 a.m. (central…

Anthera Pharmaceuticals Receives $3 Million From Cystic Fibrosis Foundation Therapeutics To Develop Sollpura

Anthera Pharmaceuticals recently announced that it received a $3 million award from the Cystic Fibrosis Foundation Therapeutics to support both the manufacturing and clinical development of Sollpura™ (liprotamase), Anthera’s new pancreatic enzyme replacement therapy. Cystic Fibrosis Foundation Therapeutics is an affiliate of the Cystic Fibrosis Foundation, a non-profit organization. Anthera Pharmaceuticals is a…

CF Therapy Kalydeco Approval Expanded to Include Children Ages 2 to 5

Vertex Pharmaceuticals Incorporated recently received approval from the United States Food and Drug Administration for Kalydeco® (ivacaftor) to treat children aged between 2 and 5 who suffer with cystic fibrosis (CF) and carry specific mutations in the CFTR gene. Children who carry one of ten different mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, including G551D,…

New Review Offers Key Updates On European Cystic Fibrosis Market

Research and Markets recently released their “Cystic Fibrosis Market in Europe 2015-2019“ report, which offers an overview of current activities involving pipeline therapeutics in the ongoing fight against cystic fibrosis. Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. Its primary symptoms include breathing difficulties, elevated…

Concert Pharmaceuticals Initiates Phase 1 Trial Of Deuterated Ivacaftor For Cystic Fibrosis

Concert Pharmaceuticals Inc. recently announced that their Phase 1 clinical program for deuterium-modified ivacaftor, a potentially disease-modifying treatment to address cystic fibrosis, has been initiated. Ivacaftor is available under the name Kalydeco®. This Phase 1 trial will be a crossover assessment to compare two different proprietary deuterium-modified compounds with the goal of…

CF Drug Developer N30 Pharmaceuticals Is Now Nivalis Therapeutics

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm committed to developing product candidates to address cystic fibrosis (CF), recently announced that the company has changed its name to Nivalis Therapeutics, Inc. Nivalis Therapeutics’ lead product candidate is N91115, a new inhibitor of S-nitrosoglutathione reductase (GSNOR) for the treatment of CF. The company’s new name, Nivalis…

Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.